VANCOUVER, BC, December 18, 2018 – Avricore Health Inc. (TSXV: AVCR) (“Avricore Health”) is pleased to announce that it has signed a Letter of Intent (LOI) with Molecular You Corporation (“Molecular You”) to distribute Molecular You’s pharmacogenomic tests designed to ensure safe and effective use of cannabis by customers in

VANCOUVER, BC, November 27, 2018 – Avricore Health Inc. (TSXV: AVCR) (“Avricore Health”) is pleased to announce that it has signed a letter of intent to review opportunities to collaborate with FoodRocket to integrate FoodRocket’s precision health offerings and genomics with the HealthTab platform across Canada. Avricore Health is actively

VANCOUVER, BC, November 1, 2018 – VANC Pharmaceuticals Inc. (“VANC”) is excited to announce that further to its news release announced October 25, 2018, the Company has received TSX Venture Exchange approval to change its name (the “Name Change”) to Avricore Health Inc. “We are pleased to have received TSX

VANC Pharmaceuticals Inc. Will Change Its Name to Avricore Health Inc. Reflecting Its New Initiatives and Focus VANCOUVER, BC, October 25, 2018 – VANC Pharmaceuticals Inc. (“VANC”) is pleased to announce that it will seek TSX Venture Exchange (the “TSXV”) approval to change the name of the Company to Avricore

VANCOUVER, BC, September 27, 2018 – VANC Pharmaceuticals Inc. (“VANC”) has contracted with Lampyon Canada Inc. to extend VANC’s proprietary education and ecommerce portal, the Corozon Platform (www.corozonplatform.com), with medical cannabis education and new sales capabilities. Corozon Platform, which is derived from the Latin word for heart, is designed to

VANCOUVER, BC, September 17, 2018 – VANC Pharmaceuticals Inc. (“VANC” or the “Company”) is pleased to announce the appointment of Philippe Ugnat as Strategic Advisor to help drive the corporate growth and strengthen the Company’s presence in the Province of Ontario and Québec. Upon joining VANC as Strategic Advisor, Philippe

Vancouver, BC (August 23, 2018) – Vanc Pharmaceuticals Inc. (TSX VENTURE: VANC) ( the “Company”) announced today that it has entered into a consulting agreement with Transcend Capital Inc. (“Transcend”) to develop and implement an investor relations program for the Company. Transcend, with offices in Vancouver, British Columbia, is a

VANCOUVER, BC, August 9, 2018 – VANC Pharmaceuticals Inc. (“VANC” or the “Company”) announces that it has issued a total of 50,458 common shares of the Company to Lampyon Canada Inc., in consideration for services rendered pursuant to the terms of a Service Agreement entered into with VANC on April